Status:
COMPLETED
HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Hepatitis B surface antigen loss/seroconversion, considered to be the ideal outcome of chronic hepatitis B virus (HBV) infection, occurs spontaneously at a low rate in inactive carriers. The research...
Detailed Description
Chronic HBV inactive carriers were enrolled in the out-patient department of Beijing Ditan Hospital. All of them were HBsAg positive and anti-HBs negative for more than 6 months with persistent undete...
Eligibility Criteria
Inclusion
- HBsAg positive and anti-HBs negative for more than 6 months
- HBeAg-negative/anti-HBe-positive
- Persistently undetectable HBV DNA with normal ALT levels, as established at 3-6 monthly intervals during the preceding 2 yrs
- Serum HBsAg levels ≤100 IU/mL, as determined on two occasions during the month prior to treatment
- Absence of previous antiviral therapy
Exclusion
- With active alcohol and/or drugs consumption
- With human immunodeficiency virus or hepatitis C virus coinfections
- With clinical evidence of cirrhosis
- With history of autoimmune hepatitis
- With hematological or psychiatric diseases
- With evidence of neoplastic diseases
- With severe cardiac or pulmonary disease
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01471535
Start Date
May 1 2008
End Date
December 1 2012
Last Update
March 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
liver disease center, Beijing Ditan Hospital
Beijing, Beijing Municipality, China, 100015